CARIS LIFE SCIENCES INC (CAI) Stock Overview
USA - NASDAQ:CAI - US1421521071 - Common Stock
CAI Key Statistics, Chart & Performance
The current stock price of CAI is 31.78 USD. In the past month the price decreased by -8.81%.
CAI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.09 | 413.22B | ||
| AMGN | AMGEN INC | 13.66 | 160.37B | ||
| GILD | GILEAD SCIENCES INC | 14.56 | 139.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.81 | 103.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.15 | 63.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.82B | ||
| ARGX | ARGENX SE - ADR | 86.3 | 48.96B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.55 | 37.77B | ||
| INSM | INSMED INC | N/A | 33.22B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.36B | ||
| BIIB | BIOGEN INC | 9.99 | 23.44B | ||
| NTRA | NATERA INC | N/A | 22.97B |
Related stock screener links
About CAI
Company Profile
Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. The company is headquartered in Irving, Texas. The company went IPO on 2025-06-18. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Company Info
CARIS LIFE SCIENCES INC
750 W John Carpenter Freeway, Suite 800
Irving TEXAS 94105 US
CEO: Timothy B. Page
Employees: 0
Phone: 18667718946
CARIS LIFE SCIENCES INC / CAI FAQ
What is the stock price of CARIS LIFE SCIENCES INC today?
The current stock price of CAI is 31.78 USD. The price increased by 6.97% in the last trading session.
What is the ticker symbol for CARIS LIFE SCIENCES INC stock?
The exchange symbol of CARIS LIFE SCIENCES INC is CAI and it is listed on the Nasdaq exchange.
On which exchange is CAI stock listed?
CAI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CARIS LIFE SCIENCES INC stock?
12 analysts have analysed CAI and the average price target is 39.91 USD. This implies a price increase of 25.57% is expected in the next year compared to the current price of 31.78. Check the CARIS LIFE SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CARIS LIFE SCIENCES INC worth?
CARIS LIFE SCIENCES INC (CAI) has a market capitalization of 8.94B USD. This makes CAI a Mid Cap stock.
How many employees does CARIS LIFE SCIENCES INC have?
CARIS LIFE SCIENCES INC (CAI) currently has 0 employees.
What are the support and resistance levels for CARIS LIFE SCIENCES INC (CAI) stock?
CARIS LIFE SCIENCES INC (CAI) has a support level at 29.7 and a resistance level at 31.79. Check the full technical report for a detailed analysis of CAI support and resistance levels.
Is CARIS LIFE SCIENCES INC (CAI) expected to grow?
The Revenue of CARIS LIFE SCIENCES INC (CAI) is expected to grow by 63.34% in the next year. Check the estimates tab for more information on the CAI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CARIS LIFE SCIENCES INC (CAI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CAI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CAI, evaluating the profitability, health, valuation and growth aspects
- CARIS LIFE SCIENCES INC (CAI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CARIS LIFE SCIENCES INC (CAI) Sales and EPS estimates to see what analysts future expectations are.
- CARIS LIFE SCIENCES INC (CAI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CARIS LIFE SCIENCES INC (CAI) Insider and Institutional Ownership to learn about the owners and their transactions.
- CARIS LIFE SCIENCES INC (CAI) Stock Chart to make your own analysis
- CARIS LIFE SCIENCES INC (CAI) Latest news and press-releases to stay up to date.
Does CARIS LIFE SCIENCES INC (CAI) stock pay dividends?
CAI does not pay a dividend.
What is the Price/Earnings (PE) ratio of CARIS LIFE SCIENCES INC (CAI)?
CARIS LIFE SCIENCES INC (CAI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.36).
What is the Short Interest ratio of CARIS LIFE SCIENCES INC (CAI) stock?
The outstanding short interest for CARIS LIFE SCIENCES INC (CAI) is 1.66% of its float. Check the ownership tab for more information on the CAI short interest.
CAI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CAI.
CAI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CAI. CAI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CAI Financial Highlights
Over the last trailing twelve months CAI reported a non-GAAP Earnings per Share(EPS) of -1.36. The EPS increased by 18.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.61% | ||
| ROE | -83.52% | ||
| Debt/Equity | 0.82 |
CAI Forecast & Estimates
12 analysts have analysed CAI and the average price target is 39.91 USD. This implies a price increase of 25.57% is expected in the next year compared to the current price of 31.78.
For the next year, analysts expect an EPS growth of -137.14% and a revenue growth 63.34% for CAI